Clinical Trials Logo

Clinical Trial Summary

Juvenile myelomonocytic leukemia (JMML) has a poor prognosis in general, with hematopoietic stem cell transplant (HSCT) remaining the standard of care for cure. Azacitidine and homoharringtonine, which exhibited a anticancer mechanism and has been widely used in patients with relapse/refractory acute myeloid leukemia (AML). However, the efficacy of these agents has not been elucidated in children with JMML. The primary objective is to assess the treatment effect on response rate in this subject population.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04505995
Study type Interventional
Source Fourth Military Medical University
Contact Wen-Yu Yang, M.D.
Phone +86-22-23909138
Email yangwenyu@ihcams.ac.cn
Status Recruiting
Phase N/A
Start date January 1, 2020
Completion date January 1, 2025

See also
  Status Clinical Trial Phase
Terminated NCT00176930 - Stem Cell Transplant for Hematological Malignancy N/A
Recruiting NCT05849662 - A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia Phase 1/Phase 2